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INTRODUCTION
Despite promising reports from British Columbia [1] and 
Louisville, Kentucky [2] about the benefits of early pionee­
ring screening programs for detection and treatment of pre­
cancer  ous stages of cervical cancer (CC), most critics did not 
accept the results and asked for randomized trials. However, 
for various reasons, including ethical, such trials were not 
feasible in large populations. Faced with this dilemma, 
most Nordic countries decided to introduce population­
based screening programs. Early trials in a few counties in 
Sweden gave promising results [3­5]. Organized screening 
programs for detection of precancerous stages of CC using 
the Papanicolaou (Pap) smear were already underway in some 
Swedish counties by the late 1950s and early 1960s. In 1967 
the Swedish Board of Health and Welfare recommended that 
all counties implement mass Pap screening of women aged 
30­49 years and to repeat the examination every 4 years. The 
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Objective: To compare profiles of a prescreening and screening cohort of women with cervical cancer regarding histopathology 
and clinical variables in order to identify those remaining at risk despite successful screening programs. By analyzing these 
profiles we hope to improve future screening methods.
Methods: The prescreening and screening cohorts consisted of 5,046 and 1,174 women, respectively, treated for cervical cancer 
at the Department of Gynecological Oncology at Radiumhemmet, Karolinska University Hospital, during the periods 1944­1957 
and 1990­2004.
Results: Mean age increased from 48.9 years to 55.3 years in the cohorts treated 1944­1957 and 1990­2004, respectively. The 
percentage of patients older than 69 years was 5.4% and 27.3% in the prescreening and screening period, respectively. A shift 
towards earlier stages at diagnosis, a reduction of squamous cervical cancer and an increase of adenocarcinoma were observed 
in the screening cohort. The percentage of adenocarcinoma was about 6 times higher among younger patients. Cases of stump 
cancer and cervical cancer associated with pregnancy have declined. Eighty­seven women in the screening cohort had a history 
of treatment for in situ carcinoma by conization; 28% of these cases developed cervical cancer within one year after conization.
Conclusion: The profile changed in the screening era indicating a need to refine screening for improved detection of in older 
women. This study, one of the largest clinical series of cervical cancer, provides an important baseline with which later studies 
can be compared to evaluate the effects of human papillomavirus vaccine and other important changes in this field.
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program rapidly gained acceptance and by 1973 the entire 
female population in the recommended age groups (except 
women in the city of Gothenburg) were offered testing. 
Many counties also offered screening to other age groups. 
Prior to 1974 the participation rate varied considerably in 
different geographic areas of Sweden from approximately 
50% up to 90%, with an average of about 70%. Subsequently 
the program expanded to cover women aged 23 to 49 every 
3 years and women aged 50­59 every 5 years. In addition, 
numerous opportunistic tests were often performed on the 
same age groups [4,6,7]. The incidence and mortality rates of 
CC in countries with well organized screening programs have 
decreased significantly since the introduction of screening. 
In Sweden the incidence of CC has declined from 20 per 
100,000 women (world stan  dard rate) in 1965 and seems to 
be leveling out at a rate of approximately 7 per 100,000 since 
the late 1990s [8]. The goal with well organized screening 
programs including treatment of detected precancerous 
lesions is that invasive cancer should be preventable. 
Although we still see significant numbers of CC, age, stage 
and histopathology profiles have changed. Consequently, and 
as a basis for refining screening, we need to carefully consider 
the new profile of these residual cases. The current study aims 
to compare the profile of histo  pathology and clinical variables 
of a prescreening cohort of CC treated at Radiumhemmet 
between 1944 and 1957 with a cohort treated at the same 
clinic during the screening era (1990­2004). 
MATERIALS AND METHODS
Early twentieth century treatment of CC in Sweden was 
centralized to Radiumhemmet in Stockholm. Initially, patients 
were referred from all over Sweden, but gradually local treat­
ment centers opened in other parts of Sweden. In more 
recent times, patients referred to Radiumhemmet come from 
hospitals in the Stockholm region, with its population of 1.8 
million. The Stockholm method of treating CC became one of 
the world’s leading methods. In order to obtain reliable data 
of treatment results, a group of pioneering doctors, including 
Prof. Heyman (1917­1947) and Prof. Kottmeier (1948­1971), 
established an early database of patients with CC that included 
information on tumor stage, histopathology, treatment and 
outcome. All cases were staged according to the International 
Federation of Gynecology and Obstetrics [FIGO] rules for 
clinical staging of CC [9] and confirmed histologically by 
biopsy. Follow­up continued until the end of life and the 
database is complete, with the exception of a small inevitable 
loss to follow­up due to emigration. Most patients were fol­
lowed­up through office visits with annual examinations at 
Radiumhemmet. In some cases follow­up was maintained 
through correspondence with patients and their local doctors. 
Death certificates were obtained from local parishes and more 
recently, from the Swedish “cause of death” register. In all, for 
the 90­year period from 1914 to 2004 the register comprised 
18,400 records. The prescreening cohort includes all 5,046 
women treated for CC at the Department of Gynecological 
Oncology at Radiumhemmet, Karolinska University Hospital, 
Solna from 1944 to 1957. The 1,174 women treated from 1990 
to 2004 at the same clinic comprise the screening period co­
hort. The two cohorts were chosen to cover a similar length 
of time. The time period of the screening cohort was selected 
30 years after the introduction of screening activities, when 
the decline of incidence of CC had levelled out at a quite 
stable level, in order to detect any changes in the profile of 
the remaining CC cases. The time period of the pre­screening 
cohort was chosen to cover the years before the start of the 
screening programme. The variables under study are age, 
stage and histopathology, as well as occurrence of stump 
cancer and cancer associated with pregnancy (defined as CC 
diagnosed during pregnancy or within 6 months of delivery). 
In the screening cohort, the number of cases previously 
treated with conization for in situ carcinoma will also be re­
corded. In Sweden the Pap smear technique has been used 
for cytological sampling in the screening programme, liquid­
based cytology and human papillomavirus (HPV) test have 
not been applied during the time period of this study.
1. Statistical analysis
The standard error (SE) of difference between percentages 
was calculated as: SE p1­p2=√   p1 (100­p1)/n1+p2(100­p2)/n2
To test the difference between two percentages, the chi 
square test with one degree of freedom was used. Yates cor­
rection was applied. The SE of the difference between means 
was calculated by t­test.
RESULTS
About 400 women were treated annually during the 1944­
1957 period (5,046 cases). Mean age was 48.9 years with a 
range of 16­91 years (SE, 0.17) and 271 women (5.4%) were 
older than 69 years. 
The annual number of cases was less than 100 in the cohort 
treated during the 1990­2004 period (1,174 cases). Mean 
age was 55.3 years with a range of 23­95 years (SE, 0.50) and 
320 women (27.3%) were older than 69 years. The difference 
between the mean age for women treated in the two periods B. Folke Pettersson, et al.
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was 6.4 years, which is statistically highly significant (p<0.01).
Women from the screening period are diagnosed at an earlier 
stage: 55% were diagnosed as stage I, compared with 17% 
during the prescreening period. Similarly, the propor  tion 
of advanced cases, stages III and IV, dropped from 29.3% to 
21.2%. The same trend is observed for both squa  mous cervi  cal 
carcinoma (SCC) (SE of diff 1.77 p<0.001) and adeno  carcino  ma 
(AC) (SE of diff 3.60 p<0.001) in the scree  ning period (Table 1).
Table 1 shows the decrease in the proportion of SCC and 
the corresponding increase in the proportion of AC in the 
screening period compared with the prescreening period co­
hort. During the prescreening period AC accounted for 5.3% 
of cases on average. Fig. 1 shows that the percentage of AC 
of the uterine cervix varied between 2% and 7% across the 
prescreening cohort. During the screening period the AC 
cases increased significantly and accounted for 25.7% of cases 
on average (p<0.001), with a marked difference observed be­
tween younger and older women. In the screening cohort, 
the percentage of AC among younger women is about 6 
times higher and in women ≥70 years about 3 times higher 
than in the prescreening cohort. Stump cancer cases were 
associated with a history of hysterectomy for benign dia  g­
nosis. The percentage dropped from 2.1% to 1.1% be  tween 
study periods.
Of the 1,174 women treated between 1990 and 2004, 87 had 
a history of prior treatment for in situ carcinoma by conization. 
In twenty­four cases (28%) conization had been performed 
in the same year that the invasive carcinoma was diagnosed 
and served as a basis for diagnosis. Of the 63 remaining cases, 
mean age 53.7 years (range, 30 to 86 years), the number of 
years between conization and diagnosis of CC were as follows: 
1­2 years for 10 women, 3­4 years for 8 women, 5­10 years for 
19 women, 11­20 years for 11 women and 21­36 years for 15 
women.
Relative incidence of cervical cancer associated with preg­
nancy decreased between study cohorts from 1.4% (1944­
1957) to 0.9% (1990­2004). The same trend is evident in the 
subgroup of women of childbearing age (<50 years). 
DISCUSSION 
The present study is based on one of the largest single 
institutional material of consecutive CC cases in the literature. 
Our results clearly show that cases treated during the 
prescreening period and during the screening period have 
different profiles regarding incidence and the distribution by 
age, stage and histopathology.
After years of doubts and criticism, it was finally shown 
that the Swedish screening program works. Today very few 
people in the field, if any, will deny its success and the results 
is comparable with that reported from other institutions 
worldwide involved in well organized screening [3,10]. 
Nevertheless, a considerable number of new cases of CC still 
occur. If we adopt the hypothetical assumption that every 
case should be preventable, it follows that each new case 
constitutes a failure. The annual number of cases treated at 
Radiumhemmet decreased from 400 in the 1950s to less than 
100 for cases included in the screening period. The National 
Swedish Cancer Registry shows a drop in the age­specific rate 
for the 35­39 year age group from 46.0 per 100,000 women 
in 1958 to 15.5 in 2004 – a 66% reduction (Fig. 2). In the 70­
74 year age group the rate dropped from 27.0 to 11.4 – a 42% 
reduction. The Swedish cause of death register shows an age 
standardized mortality rate of 7.7 per 100,000 women for CC 
in 1959 and 2.8 in 2004 (Fig. 3). 
Our study demonstrates a shift towards earlier stages of CC 
diagnosed during the screening period compared with the 
prescreening period. The same trend is observed for both SCC 
and AC in the screening period, contradicting a recent report 
from the Netherlands [11]. 
Fig. 1. Percentage of adenocarcinoma of the uterine cervix by age 
and by treatment period.
Table 1. Stage distribution by histopathology and treatment period
Treatment period  No. %             Stage
1944-1957 5,046 I II III IV
    SCC 94.7 788 2,571 1,085 335
    Adenocarcinoma   5.3   69   135     44   19
1990-2004 1,174
    SCC 74.20 464 210 145 54
    Adenocarcinoma 25.80 187   60   39 15
SCC, squamous cervical carcinoma.Cervical cancer in the screening era
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The change in incidence and stage distribution in the two 
cohorts is also connected with change in social conditions, 
availability to health care and in exposure to risk factors for CC. 
Increased knowledge in the etiology to CC (that CC mainly 
is a sexually transmitted disease caused by high risk HPV) 
have led to increased information how to prevent spread of 
gynaecological infections and thereby contributed to changed 
sexual behaviors and a decreased incidence of CC. In addition 
reduced tobacco use from the 1990s [12] has probably affec­
ted the incidence as it is known as a cofactor for cervical carci­
nogenesis. 
We observed a change in the distribution of histopathology, 
the proportion of AC found in the screening cohort increased 
on average about fivefold, especially in the younger age groups, 
which is in accordance with data in other reports [10]. The 
reasons to the increase in AC have been discussed in the li  tera­
ture. Studies have shown that SCC and AC of the cervix seem 
to share most risk factors, with the exception of smoking (for 
which risk is elevated for SCC but not AC) [13­15]. Like SCC HPV 
appears to be the key risk factor for AC. However, it may be 
concluded that our understanding of the epidemiology and 
natural history of CC is still incomplete. The overwhelming ma­
jority of the literature addressing this subject to date has dealt 
with SCC. A study of age groups and birth cohorts, based on the 
Swedish National Cancer Registry for 1958­1980, of women 
born between 1879 and 1959 (including 17,100 cases of CC) 
showed an increase in incidence of AC in the 25­29 year age 
group from 0.7 per 100,000 for women born from 1935 to 
1939, to 1.2 for women born from 1950 to 1954. Similarly, for 
Fig. 2. Carcinoma of the uterine cervix. Age specific incidence rates/100,000 in Sweden in age groups 35-39 to 60-64. Data from the National 
Swedish Cancer Registry.
Fig. 3. Age standardized mortality rates for carcinoma of the uterine 
cervix in Sweden per 100,000 women. The Swedish Cause of Death 
Register.B. Folke Pettersson, et al.
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the 30­34 year age group an increase was seen from 1.0 for 
women born between 1930 and 1934 to 1.9 for women born 
between 1945 and 1949 [7,16]. In a subsequent study, based 
on the same material but extended to 1992, a similar increase 
in incidence of AC was seen during the last decade as well 
[17]. This increase in AC in the later birth cohorts is probably 
related to greater exposure to HPV after the sexual revolution 
in the 1960s [18]. 
In the present study we also noted a change in age distribu­
tion between the two cohorts. In the prescreening cohort, 271 
women (5.4%) were aged ≥70, which corresponds well to 
the per  centage of the Swedish population at risk at that time 
(7.8%). In the screening cohort, both mean age (p< 0.001) 
and percentage of patients in older age groups are hi  gher 
com  pared with the Swedish population at risk at that time. In 
all, 320 women (27.3%) were aged ≥70, which far exceeds 
the expected number (18.2%), considering the in  crea  se in 
po  pu  lation at risk within that age group in Sweden. With 
the im  plementation of screening and patient com  pliance 
with the proposed screening intervals, it was pre  sumed that 
women would be protected for their entire lives. Our fin  ding 
of an increased proportion of older women (≥70) among 
the women treated today may indicate that there is a need 
to re  fi  ne the screening program to include older wo  men. Fu­
rther  more, we find the proportion of AC among older women 
trea  ted today to be lower than among younger women, while 
the proportion of AC was more even  ly distributed among di­
ffe  rent age groups during the prescreening period. Under 
the tentative hypothesis that the higher percentage of ACs 
after introduction of screening may serve as an indi  ca  tor of 
screening efficacy, it may be surmised that current screening 
programs do not provide the protection we had assumed for 
the older age groups. In other words, ACs in older age groups 
have been diluted by undetected cases of SCC. We must also 
take into consideration that postmenopausal women have 
undergone hormonally­related physiological chan  ges including 
retraction of the transformation zone, which results in fewer de­
squamated cells on the Pap slide and makes it more difficult 
to obtain an adequate sample. There  fore we must ask if today’s 
sampling methods are suitable for the postmenopausal po­
pulation. In addition the cytological screening with Pap smear 
seem to be less effective in detec  ting precursor lesions of AC 
[18­20], than of SCC. 
The Pap smear technique was described already in 1928 by 
both Babes [21] about the potential for using desquamated 
cellular material from the uterine cervix to serve as a diagnostic 
tool for detection of CC. Accuracy of the Pap smear technique 
for early detection of CC and precursor lesions has been eva­
luated through various means with differing results. False nega­
tive rates ranging from 5% to 40% have been reported [22]. 
Since all precursor lesions of ACs and nearly all invasive ACs 
seem to be positive for high risk HPV, the incorporation of high 
risk HPV testing in cervical cancer screening programmes is 
likely to decrease markedly the incidence of cervical AC [23]. 
Furthermore, a combination of HPV testing and cytological eva­
luation following conization has shown to significantly im  prove 
reliability of follow­up surveillance [24]. 
In 2006, over 60% of patients with cervical squamous carci­
noma in Sweden occurred in postmenopausal women, aged 
50 years or older [8]. Efficacy of cytological screening is known 
to be lower in higher age groups, and is only effective in 20% 
of women aged 50 years or older, compared with women aged 
30–35 years old [25]. It was shown that the high risk HPV test 
was three times as sensitive as the Pap test in detecting grade 
2 and 3 CIN lesions in women aged 50–65 years [26]. However 
in very old women the diagnostic difficulties may remain since 
the occurrence of HPV is not well­known and may be less co­
mmon [10]. 
We must also realize that, even with good screening tools, 
some women will refuse to participate in screening and will 
not be covered by the screening programs, which has been 
suggested as the major reason for cervical cancer morbidity [27]. 
According to a recent report the coverage of the CC screening 
programs in the European Union member states was below 
80% (range, 10 to 79%) [28]. In Sweden the coverage was 
reported to be 73% [28]. The category of women who avoid 
participation, despite being called to screening, often includes 
women of lower socioeconomic status, as well as women of 
higher socioeconomic status who do not consider themselves 
to be at risk [29­31]. Studies have shown that lack of knowledge 
and information about the benefits and role of screening are 
important factors for non­compliance [32,33]. Furthermore, 
we often see immigrant groups for whom screening was not 
available in their country of origin. More than 15% of newly 
diagnosed CC cases, treated at Radiumhemmet in 1987­88, 
were immigrant women, especially from non­Nordic countries 
[16]. Women in the “false negative” screening results category 
are sometimes incorrectly classified as having tumors that 
arise and grow rapidly. More thorough investigation may 
reveal that women with these rapidly growing tumors have 
a history of inadequately treated precancerous stages. Such 
treatment may have involved cold­knife, laser, or diathermy 
conization. In this study we noted cases of invasive cancer 
appearing 1­36 years after conization for previous in situ carci­
noma. Consequently, these women, who were treated for 
pre  cancerous stages, still comprise a high­risk group and should 
be carefully monitored. In a record linkage study using data 
from the National Swedish Cancer Registry, we found that Cervical cancer in the screening era
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among 56,116 women treated for CC in situ and followed­up 
by record­linkage with the invasive cancer register, an in  crea­
sing number fell victim to invasive carcinoma over time. The 
relative risk for this group of women was found to be twice 
that of women in the general population after 20 years. In wo­
men ≥50 years when treated for in situ lesions, relative risk was 
6 times higher compared with women at large [34]. Obviously, 
once women have been diagnosed with carcinoma in situ, they 
belong to a high­risk category for developing CC and should 
be carefully monitored. 
We also found in the present study that stump cancer was 
be  ing diagnosed long after subtotal hysterectomies for 
benign conditions. This subject was covered in an earlier 
study from our institution [35]. These women should be 
covered in the routine screening programs, and should be re­
minded to continue screening after the surgery for subtotal 
hysterectomy. Furthermore, we saw cases in conjunction with 
pregnancy and our results have recently been published [36]. 
Pregnant women should also be reminded to do routine cyto­
logical test according to the screening program. 
In conclusion, the screening activities have markedly affected 
the incidence and we found an increase in ACs and CC in older 
women. Efficient use of screening resources necessitates con­
tinuous monitoring of incidence and mortality trends within 
different population strata. Quite obviously, conventional Pap 
smear technique, has been effective in significantly reducing 
incidence and mortality rates for CC. Nevertheless, the challen  ge 
remains to increase coverage to screening, provide protection 
for older women and to find a working technique that can be 
used for large­scale population screening, capable of iden  tifying 
the remaining cases that currently still progress to invasive car  ci­
nomas. The next tier in the preventive work is to develop safe 
methods for the treatment of detected precancerous lesions. 
It is important to realize that to avoid losing what we have hi­
therto gained through screening, we must continue the battle 
against CC. This retrospective study, to our knowledge one of 
the largest in the literature, provides an important baseline for 
future improvements of the screening methods.
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